DIVA Expertise is the leading global scientific partner for companies in the health, nutraceuticals and cosmetics industries seeking to evaluate the efficacy of an active ingredient or product directly on human adipose and skin tissue, ex vivo and in vitro. DIVA Expertise offers turnkey R&D projects – using unique, scientifically validated predictive human biological models – to provide industrial players with robust mechanistic evidence that accelerates and ensures the safe market launch of their innovations in cosmetics, nutraceuticals, and pharma metabolism/obesity.

What sets DIVA apart: DIVA biobank offering and innovative in vitro and ex vivo models enable preclinical expertise that closely aligns with the physiology of human adipose tissue, by working with real human biological materials from donors and adhering to the 3Rs principle (reduction of animal testing).

Astrum is an international contract research organization (CRO) providing full-service clinical development solutions to biotech companies worldwide. With a team of over 250 professionals across Europe, Astrum combines the scientific rigor of a large CRO with the agility and responsiveness that emerging biotech sponsors need to advance their programs efficiently.

Astrum operates a proprietary 64-bed Phase I clinical unit in Porto, Portugal, inspected by EMA, FDA, ANVISA & enabling early-phase studies including single and multiple ascending dose, drug-drug interaction, bioequivalence, and food effect trials in healthy volunteers and patients, including critical indications through its integrated intensive care unit.

Beyond early phase, Astrum offers strong experience in Phase II and Phase III clinical trials, with particular expertise in oncology, immunology, and central nervous system (CNS) indications. Astrum also holds CIR (Crédit Impôt Recherche) accreditation in France, allowing French sponsors to optimize their R&D investment through significant tax benefits. Astrum is headquartered in Europe, with a large operational coverage across countries and a long-standing US partnership ensuring transatlantic trial execution.

Porsolt is a Center of Excellence in Non Clinical Pharmacology with over 40 years of experience in delivering high-quality research services to the pharmaceutical, biotechnology, and academic sectors. Renowned for its scientific expertise and innovation, Porsolt offers a comprehensive portfolio of services that span safety & efficacy pharmacology, toxicology, histology, PK/PD, and Biomarkers assessment, helping clients advance their drug discovery and development programs efficiently and effectively.

With a strong focus on client collaboration, flexibility, and tailored solutions, Porsolt has established itself as a trusted partner in driving innovation in multiple therapeutic areas including CNS, CardioVascular, Inflammation, Pain, Metabolic diseases and more.

Their advanced histology capabilities play a pivotal role in this process, offering unparalleled insights into tissue morphology and pathology.

Atlantic Bone Screen is a specialized preclinical CRO with recognized expertise in bone and joint health, as well as oncology.

They provide both in vitro and in vivo non-GLP evaluations of drug candidates, supporting the demonstration of product efficacy in comparison with standard of care or competitor products.

Atlantic Bone Screen’s capabilities include:
• In vitro models using tumor cell lines, macrophages, chondrocytes, osteoblasts and osteoclasts, as well as keratinocytes, fibroblasts, and skin explants
• In vivo models in rats and mice, including both chemically and surgically induced pathologies, supported by their in-house animal facility

Novalix is a premier contract research organization, dedicated to improving the critical early stages of drug discovery by combining exceptional scientific talent and exclusive technology with a comprehensive portfolio of world-class chemistry, biophysics and pharmacology capabilities. Novalix works collaboratively with its clients to meet the most complex scientific challenges, and its innovative partnerships with leading instrument makers and academic institutions help it continually expand the possibilities of human health.

From early discovery to candidate selection, Novalix tailors every project around clients’ needs and goals. Every engagement is driven by experienced scientists using exceptional technology to increase the odds of success at each stage.

Comprehensive capabilities are included into five centers of excellence: Chemistry, Biophysics, Pharmacology and DMPK, Drug Discovery, and Cosmetics.
A wide range of areas are then covered, including medicinal chemistry, cheminformatics, synthetic chemistry, process chemistry and scale-up, biophysics (NMR, MS, SPR), protein production with a focus on GPCRs, and structural biology techniques such as cryo-EM, protein x-ray crystallography, NMR. Novalix also excels in in vitro and in vivo pharmacology, translational science, biobanking, histology, ADME-DMPK, and pre-formulation.

Scientific expertise includes diverse modalities, such as small molecules, biologics (mAbs, ADCs), and PROTACs. The company focuses on various therapeutic areas, namely oncology, immuno-inflammation, infectious diseases, fibrosis, kidney diseases, osteoarthritis, and metabolic disorders.

State-of-the-art facilities are located in France and Tunisia, with business representative offices in the United States and Japan, ensuring a global presence and reach.